[HTML][HTML] Identification of isoform-selective hydroxamic acid derivatives that potently reactivate HIV from latency

EFW Heffern, R Ramani, G Marshall, GB Kyei - Journal of Virus Eradication, 2019 - Elsevier
Objectives Current antiretroviral therapy can suppress HIV replication, increase CD4 count
and result in increased lifespan. However, it cannot eradicate the virus due to the presence …

[HTML][HTML] Latency reversal agents affect differently the latent reservoir present in distinct CD4+ T subpopulations

J Grau-Expósito, L Luque-Ballesteros, J Navarro… - PLoS …, 2019 - journals.plos.org
Latency reversal agents (LRAs) have proven to induce HIV-1 transcription in vivo but are
ineffective at decreasing the size of the latent reservoir in antiretroviral treated patients. The …

Latency reversal and viral clearance to cure HIV-1

DM Margolis, JV Garcia, DJ Hazuda, BF Haynes - Science, 2016 - science.org
BACKGROUND A central challenge to emerging efforts to cure HIV infection is the
persistence of quiescent but replication-competent proviral genomes in resting CD4+ T …

Flavonoid-based inhibition of cyclin-dependent kinase 9 without concomitant inhibition of histone deacetylases durably reinforces HIV latency

C Schonhofer, J Yi, A Sciorillo… - Biochemical …, 2021 - Elsevier
While combination antiretroviral therapy (cART) durably suppresses HIV replication, virus
persists in CD4+ T-cells that harbor latent but spontaneously inducible and replication …

[HTML][HTML] HDAC inhibition induces HIV-1 protein and enables immune-based clearance following latency reversal

G Wu, M Swanson, A Talla, D Graham, J Strizki… - JCI insight, 2017 - ncbi.nlm.nih.gov
Promising therapeutic approaches for eradicating HIV include transcriptional activation of
provirus from latently infected cells using latency-reversing agents (LRAs) and immune …

[HTML][HTML] Broad activation of latent HIV-1 in vivo

K Barton, B Hiener, A Winckelmann… - Nature …, 2016 - nature.com
The 'shock and kill'approach to cure human immunodeficiency virus (HIV) includes
transcriptional induction of latent HIV-1 proviruses using latency-reversing agents (LRAs) …

c-Myc and Sp1 contribute to proviral latency by recruiting histone deacetylase 1 to the human immunodeficiency virus type 1 promoter

G Jiang, A Espeseth, DJ Hazuda… - Journal of virology, 2007 - Am Soc Microbiol
Histone deacetylase (HDAC) inhibitors such as valproic acid (VPA) induce the expression of
quiescent proviral human immunodeficiency virus type 1 (HIV-1) and may deplete proviral …

[HTML][HTML] Chidamide, a histone deacetylase inhibitor-based anticancer drug, effectively reactivates latent HIV-1 provirus

W Yang, Z Sun, C Hua, Q Wang, W Xu, Q Deng… - Microbes and …, 2018 - Elsevier
Although combination antiretroviral therapy (cART) is highly effective in suppressing human
immunodeficiency virus type 1 (HIV-1) replication, it fails to eradicate the virus from HIV-1 …

The molecular biology of HIV latency

G Khoury, G Darcis, MY Lee, S Bouchat… - HIV vaccines and cure …, 2018 - Springer
HIV remains incurable due to the existence of a reservoir of cells that harbor intact integrated
genomes of the virus in the absence of viral replication. This population of infected cells …

Neurotoxicity with high-dose disulfiram and vorinostat used for HIV latency reversal

JH McMahon, VA Evans, JSY Lau, J Symons… - Aids, 2022 - journals.lww.com
Objective: The aim of this study was to examine whether administering both vorinostat and
disulfiram to people with HIV (PWH) on antiretroviral therapy (ART) is well tolerated and can …